Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance.
Schaison
G
G
Leverger
G
G
Bancillon
A
A
Marty
M
M
Olive
D
D
Cornu
G
G
Griscelli
C
C
Lemerle
S
S
Harousseau
J L
JL
Bonnet
M
M
D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D011897:Random Allocation; D012306:Risk; D014750:Vincristine / Q000008:administration & dosage
D000677:Amsacrine; D003561:Cytarabine; D014750:Vincristine; D015122:Mercaptopurine; D008727:Methotrexate